Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
229 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06489808 | Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL | recruiting | Phase 2 | 89 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 8, 2024 | clinicaltrials |
| NCT06490549 | An Epidemiological Study to Investigate the Characteristics of RSV Infection in Adult Hematopoietic Cell Transplant Recipients or Hematological Malignancies Patients in Tianjin HI (Hematology Institute) | unknown | — | 500 | Institute of Hematology & Blood Diseases Hospital, China |
| 1 |
| Jul 8, 2024 |
| clinicaltrials |
| NCT05870475 | Pegylated Interferon α-2b in Combination With Ruxolitinib for Treating Hydroxyurea-resistant/Intolerant PV(PV) | recruiting | Phase 2 | 94 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT06447090 | VMAC+DLI Treatment of Patients With Relapse of AML After Allo-HSCT(VMAC+DLI) | recruiting | Phase 2 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05676710 | Efficacy and Safety of PI3K Inhibitors in Relapsed/Refractory Large Granular T Lymphocytic Leukemia | completed | Phase 1 | 8 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT06415708 | Obinutuzumab Combined With Bendamustine in the Treatment of Mature B-cell Lymphoma | unknown | Phase 2 | 134 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06367374 | MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL | not yet recruiting | Phase 2 | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Apr 16, 2024 | clinicaltrials |
| NCT06302699 | Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma | unknown | — | 80 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06158269 | DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma | recruiting | Phase 2 | 40 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 6, 2023 | clinicaltrials |
| NCT06133556 | Conditioning Regimen Containing Melphalan and Cladribine for Refractory / Relapsed AML | not yet recruiting | Phase 2 | 237 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 15, 2023 | clinicaltrials |
| NCT06087419 | A Prospective Clinical Study of Bridging alloHSCT After Treatment With Obinutuzumab in Combination With Chidamide and Venetoclax in RR Ph-ALL and B-cell Lymphoma Patients | unknown | Phase 1 / Phase 2 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Nov 2, 2023 | clinicaltrials |
| NCT05846750 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone Lymphoma | recruiting | Phase 2 | 59 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 19, 2023 | clinicaltrials |
| NCT05846763 | Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Follicular Lymphoma in Real World Study | recruiting | — | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05519384 | Safety and Preliminary Efficacy of JK500 Cell Injection in Relapsed/Refractory Pediatric Acute Myeloid Leukemia | unknown | Early Phase 1 | 12 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 28, 2022 | clinicaltrials |
| NCT05603156 | A Study of Olverembatinib Combined With Inotuzumab Ozogamicin in the Treatment ph+ ALL With MRD Persistent Positive | unknown | N/A | 46 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Nov 2, 2022 | clinicaltrials |
| NCT05578625 | ctDNA Methylation Sequencing for Myeloma | unknown | — | 66 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Oct 13, 2022 | clinicaltrials |
| NCT05549973 | Anlotinib Hydrochloride Capsule Monotherapy and Combination Therapy Relapsed and Refractory Multiple Myeloma | unknown | Phase 1 | 32 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 22, 2022 | clinicaltrials |
| NCT05536700 | Using Mass Spectrometry (EasyM) Detecting Minimal Residual Disease (MRD) in Multiple Myeloma | unknown | — | 67 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 13, 2022 | clinicaltrials |
| NCT05335226 | Combined Haploidentical and Umbilical Cord Blood Allogeneic Stem Cell Transplantation in Patients With Acute Leukemia | unknown | N/A | 116 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT03173612 | The Efficiency of CAMS (Chinese Academy of Medical Sciences)-2016 Trial for Pediatric Acute Myeloid Leukemia | unknown | N/A | 132 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 3, 2022 | clinicaltrials |
| NCT05287984 | Zanubrutinib Followed Zanubrutinib Plus FCR / BR in Newly Diagnosed Symptomatic CLL/SLL(ZFCR/ZBR) | unknown | Phase 2 | 63 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Mar 31, 2022 | clinicaltrials |
| NCT03837873 | DLCL002 Protocol for Patients With High Risk Aggressive B-cell Lymphoma | unknown | Phase 2 | 118 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 26, 2022 | clinicaltrials |
| NCT05137886 | PD-1 Inhibitor Combined With Decitabine Followed by ASCT as Second-line Therapy for Relapsed or Refractory Classic Hodgkin's Lymphoma | unknown | Phase 2 | 47 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Dec 17, 2021 | clinicaltrials |
| NCT04992377 | R-EPOCH in Combination With Ibrutinib for Patients With Classical RT of CLL(BDHRT001) | unknown | Phase 2 | 30 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT04696705 | Allogeneic γδ T Cells Immunotherapy in r/r Non-Hodgkin's Lymphoma (NHL) or Peripheral T Cell Lymphomas (PTCL) Patients | unknown | Early Phase 1 | 10 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jan 6, 2021 | clinicaltrials |
| NCT04453345 | TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL | unknown | Phase 2 / Phase 3 | 42 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 1, 2020 | clinicaltrials |
| NCT04028440 | γδT Cells Immunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma (NHL) | unknown | Early Phase 1 | 6 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Sep 26, 2019 | clinicaltrials |
| NCT04008888 | a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients | unknown | N/A | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jul 5, 2019 | clinicaltrials |
| NCT03980002 | A Prospective Multicenter Phase 2 Study of FCR/BR Alternating With Ibrutinib in Treatment-naive Patients With CLL(BDHCLL001) | recruiting | Phase 2 | 50 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 1 | Jun 10, 2019 | clinicaltrials |
Data updated 22 days agoSource updated unknownsource: clinicaltrials